Eliem Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Eliem Therapeutics | 10-K: Annual report
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pimblett Emily
Eliem Therapeutics | 8-K: Current report
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(47.5%),Peter Kolchinsky(47.5%), etc.
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Braden M Leonard(8.5%),BML Investment Partners, L.P.(7.9%)
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(47.7%),Peter Kolchinsky(47.7%), etc.
Eliem Therapeutics: Q3 2023 Earnings Report
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Eliem Therapeutics | 10-Q: Q2 2023 Earnings Report
Eliem Therapeutics | 8-K: Current report
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Tate Simon
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ratcliffe Liam
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dunn Judith
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rosenberg Adam Joseph
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Executive Chairman Levin Andrew David
Eliem Therapeutics | 8-K: Current report
Eliem Therapeutics | 8-K: Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
No Data